{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T09:01:22Z","timestamp":1780304482397,"version":"3.54.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004095","name":"Kyowa Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bone.2025.117649","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T05:10:57Z","timestamp":1758085857000},"page":"117649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Advancing Patient Evidence in XLH (APEX): Baseline analysis of a global data unification program"],"prefix":"10.1016","volume":"201","author":[{"given":"Thomas O.","family":"Carpenter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Haffner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik A.","family":"Imel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Ozono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Sandilands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Joos-Vandewalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheuk","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Kanematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith P.","family":"McCullough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2025.117649_bb0005","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13023-019-1014-8","article-title":"FGF23 and its role in X-linked hypophosphatemia-related morbidity","volume":"14","author":"Beck-Nielsen","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.bone.2025.117649_bb0010","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"15","author":"Haffner","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.bone.2025.117649_bb0015","doi-asserted-by":"crossref","first-page":"e1249","DOI":"10.1210\/clinem\/dgab739","article-title":"Musculoskeletal features in adults with X-linked hypophosphatemia: an analysis of clinical trial and survey data","volume":"107","author":"Javaid","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2025.117649_bb0020","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1530\/EC-20-0291","article-title":"Clinical guidelines for burosumab in the treatment of XLH in children and adolescents: British paediatric and adolescent bone group recommendations","volume":"9","author":"Padidela","year":"2020","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.bone.2025.117649_bb0025","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s00431-011-1529-z","article-title":"Clinical practice: diagnostic approach to the rachitic child","volume":"170","author":"Rajah","year":"2011","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.bone.2025.117649_bb0030","first-page":"4075","article-title":"X-linked hypophosphatemia: a search for gender, race, anticipation, or parent of origin effects on disease expression in children","volume":"81","author":"Whyte","year":"1996","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2025.117649_bb0035","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/jbmr.4486","article-title":"An expert perspective on phosphate dysregulation with a focus on chronic hypophosphatemia","volume":"37","author":"Aljuraibah","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2025.117649_bb0040","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s00198-021-05997-1","article-title":"Burden of disease and clinical targets in adult patients with X-linked hypophosphatemia","volume":"32","author":"Giannini","year":"2021","journal-title":"A comprehensive review. Osteoporos Int"},{"key":"10.1016\/j.bone.2025.117649_bb0045","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/EJE-08-0818","article-title":"Incidence and prevalence of nutritional and hereditary rickets in southern Denmark","volume":"160","author":"Beck-Nielsen","year":"2009","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.bone.2025.117649_bb0050","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1507\/endocrj.EJ15-0275","article-title":"Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment","volume":"62","author":"Endo","year":"2015","journal-title":"Endocr. J."},{"key":"10.1016\/j.bone.2025.117649_bb0055","doi-asserted-by":"crossref","first-page":"e871","DOI":"10.1210\/clinem\/dgz203","article-title":"Prevalence and mortality of individuals with X-linked hypophosphatemia: a United Kingdom real-world data analysis","volume":"105","author":"Hawley","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2025.117649_bb0060","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1530\/EJE-15-0515","article-title":"Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications","volume":"174","author":"Rafaelsen","year":"2016","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.bone.2025.117649_bb0065","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/jbmr.340","article-title":"A clinician\u2019s guide to X-linked hypophosphatemia","volume":"26","author":"Carpenter","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2025.117649_bb0070","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s13023-023-02882-4","article-title":"The international X-linked hypophosphatemia (XLH) registry: first interim analysis of baseline demographic, genetic and clinical data","volume":"18","author":"Ariceta","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.bone.2025.117649_bb0075","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvab070","article-title":"Patient-reported complications, symptoms, and experiences of living with X-linked hypophosphatemia across the life-course","volume":"5","author":"Cheung","year":"2021","journal-title":"J. Endocrin. Soc."},{"key":"10.1016\/j.bone.2025.117649_bb0080","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/s13023-022-02452-0","article-title":"Health-related quality of life of X-linked hypophosphatemia in Spain","volume":"17","author":"Yanes","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.bone.2025.117649_bb0085","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11657-021-00879-9","article-title":"Diagnosis and management of X-linked hypophosphatemia in children and adolescent in the Gulf cooperation council countries","volume":"16","author":"Al Juraibah","year":"2021","journal-title":"Arch. Osteoporos."},{"key":"10.1016\/j.bone.2025.117649_bb0090","series-title":"CRYSVITA [summary of product characteristics]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/crysvita-epar-product-information_en.pdf","author":"European Medicines Agency","year":"2022"},{"key":"10.1016\/j.bone.2025.117649_bb0095","series-title":"Crysvita (Burosumab-Twza) Injection, for Subcutaneous Use [Full Prescribing Information]. Princeton, NJ: Kyowa Kirin. https:\/\/www.crysvitahcp.com\/assets\/files\/full-prescribing-information.pdf","year":"2023"},{"key":"10.1016\/j.bone.2025.117649_bb0100","series-title":"Kyowa Kirin announces approval of Crysvita\u00ae (burosumab) for the treatment of FGF23-related hypophosphatemic rickets and osteomalacia in Japan [press release]. https:\/\/www.kyowakirin.com\/media_center\/news_releases\/2019\/e20190920_01.html","author":"Kirin","year":"2019"},{"key":"10.1016\/j.bone.2025.117649_bb0105","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1172\/JCI72829","article-title":"Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia","volume":"124","author":"Carpenter","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bone.2025.117649_bb0110","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2025.117649_bb0115","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2025.117649_bb0120","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1210\/clinem\/dgab729","article-title":"Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia","volume":"107","author":"Linglart","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2025.117649_bb0125","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","article-title":"Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period","volume":"105","author":"Portale","year":"2019","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2025.117649_bb0130","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1210\/jc.2015-1551","article-title":"Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23","volume":"100","author":"Imel","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2025.117649_bb0135","doi-asserted-by":"crossref","DOI":"10.1177\/20406223241247643","article-title":"Real-world non-interventional post-authorization safety study of long-term use of burosumab in children and adolescents with X-linked hypophosphatemia: first interim analysis","volume":"15","author":"Boot","year":"2024","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.bone.2025.117649_bb0140","doi-asserted-by":"crossref","first-page":"e998","DOI":"10.1210\/clinem\/dgad223","article-title":"Effects of burosumab treatment on mineral metabolism in children and adolescents with X-linked hypophosphatemia","volume":"108","author":"Ewert","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2025.117649_bb0145","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3389\/fped.2020.00048","article-title":"Positive response to one-year treatment with burosumab in pediatric patients with X-linked hypophosphatemia","volume":"8","author":"Mart\u00edn Ramos","year":"2020","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.bone.2025.117649_bb0150","series-title":"Rare diseases at FDA. https:\/\/www.fda.gov\/patients\/rare-diseases-fda","author":"US Food and Drug Administration","year":"2024"},{"key":"10.1016\/j.bone.2025.117649_bb0155","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-036367","article-title":"Long-term outcomes for Asian patients with X-linked hypophosphataemia: rationale and design of the SUNFLOWER longitudinal, observational cohort study","volume":"10","author":"Kubota","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.bone.2025.117649_bb0160","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s13023-020-01434-4","article-title":"The international X-linked hypophosphataemia (XLH) registry (NCT03193476): rationale for and description of an international, observational study","volume":"15","author":"Padidela","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.bone.2025.117649_bb0165","series-title":"X-linked hypophosphatemia disease monitoring program [NCT03651505]. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03651505","author":"ClinicalTrials.gov","year":"2025"},{"key":"10.1016\/j.bone.2025.117649_bb0170","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1210\/clinem\/dgae069","article-title":"The diagnostic odyssey in children and adolescents with X-linked hypophosphataemia: population-based, case-control study","volume":"109","author":"Boardman-Pretty","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2025.117649_bb0175","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1471127","article-title":"Advancing patient evidence in XLH (APEX): rationale and design of a real-world XLH global data unification program","volume":"16","author":"Brandi","year":"2025","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.bone.2025.117649_bb0180","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1210\/clinem\/dgad597","article-title":"LMS-based pediatric reference values for parameters of phosphate homeostasis in the HARP cohort","volume":"109","author":"Pott","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2025.117649_bb0185","series-title":"CDC growth charts data files. https:\/\/www.cdc.gov\/growthcharts\/cdc-data-files.htm","author":"National Center for Health Statistics","year":"2024"},{"key":"10.1016\/j.bone.2025.117649_bb0190","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0022-3476(05)81738-X","article-title":"Normal values for random urinary calcium to creatinine ratios in infancy","volume":"123","author":"Sargent","year":"1993","journal-title":"J. Pediatr."},{"key":"10.1016\/j.bone.2025.117649_bb0195","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1373\/clinchem.2011.177741","article-title":"Closing the gaps in pediatric laboratory reference intervals: a CALIPER database of 40 biochemical markers in a healthy and multiethnic population of children","volume":"58","author":"Colantonio","year":"2012","journal-title":"Clin. Chem."},{"key":"10.1016\/j.bone.2025.117649_bb0200","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00223-023-01172-2","article-title":"Disease manifestations and complications in Dutch X-linked hypophosphatemia patients","volume":"114","author":"Bosman","year":"2024","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2025.117649_bb0205","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1210\/js.2018-00365","article-title":"The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey","volume":"3","author":"Skrinar","year":"2019","journal-title":"J. Endocrin. Soc."},{"key":"10.1016\/j.bone.2025.117649_bb0210","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1210\/clinem\/dgaa495","article-title":"Growth curves for children with X-linked hypophosphatemia","volume":"105","author":"Mao","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2025.117649_bb0215","doi-asserted-by":"crossref","DOI":"10.1093\/jbmrpl\/ziae118","article-title":"Impact of X-linked hypophosphatemic rickets\/osteomalacia on health and quality of life: baseline data from the SUNFLOWER longitudinal, observational cohort study","volume":"8","author":"Namba","year":"2024","journal-title":"JBMR Plus"},{"key":"10.1016\/j.bone.2025.117649_bb0220","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1093\/jbmr\/zjae127","article-title":"Nephrocalcinosis and kidney function in children and adults with X-linked hypophosphatemia: baseline results from a large longitudinal study","volume":"39","author":"Portale","year":"2024","journal-title":"J. Bone Miner. Res."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328225002613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328225002613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T08:02:10Z","timestamp":1780300930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328225002613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":44,"alternative-id":["S8756328225002613"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2025.117649","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancing Patient Evidence in XLH (APEX): Baseline analysis of a global data unification program","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2025.117649","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117649"}}